Diagnosis and Treatment of Systemic Juvenile Idiopathic Arthritis (sJIA) in Pediatric Age Groups
- References
1. Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles‐Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis:Therapeutic approaches for Oligoarthritis, Temporomandibular joint arthritis, and Systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2022 Apr;74(4):553-69. doi: 10.1002/acr.24853
2. Ravelli A, Consolaro A, Horneff G, et al.Treating juvenile idiopathic arthritis to target: recommendations of an international task force Annals of the Rheumatic Diseases 2018;77:819-828.doi:10.1136/annrheumdis-2018-213030.
3. Hinze et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany 2018. Pediatric Rheumatology (2018) 16:7. DOI 10.1186/s12969-018-0224-2
4. Amer YS, Elzalabany MM, Omar TI, Ibrahim AG, Dowidar NL. The 'Adapted ADAPTE': an approach to improve utilization of the ADAPTE guideline adaptation resource toolkit in the Alexandria Center for Evidence-Based Clinical Practice Guidelines. J EvalClinPract. 2015 Dec;21(6):1095-106. doi: 10.1111/jep.12479
5. Fervers B, Burgers JS, Voellinger R, Brouwers M, Browman GP, Graham ID, Harrison MB, Latreille J, Mlika-Cabane N, Paquet L, Zitzelsberger L. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ quality & safety. 2011 Mar 1;20(3):228-36.
6. AGREE (II) Instrument available from the www.agreecollaboration.org/instrument/ (downloaded free).
7. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369: 767-79.
8. Lee JJY, Schneider R. Systemic Juvenile Idiopathic Arthritis. Pediatr Clin North Am. 2018;65(4):691-709.
9. Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 2019; 46(2):190-7.
10. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112–7
11. Modesto C, Antón J, Rodriguez B, Bou R, Arnal C, Ros J, et al. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scandinavian Journal of Rheumatology 2010: 39; 472–9.
12. Abou El-Soud A, El-Najjar A, El-Shahawy E, Amar H, Hassan T, Abd-Allaha S, Ragab H. Prevalence of juvenile idiopathic arthritis in Sharkia Governorate, Egypt: epidemiological study. Rheumatol Int 2013; 33:2315–22
13. Consolaro A, Ravelli A. Defining criteria for disease activity states in juvenile idiopathic arthritis. Rheumatology 2016;55(4):595–6.
14. Salah S, Hamshary A, Lotfy H, Abdel Rahman H. Juvenile Idiopathic Arthritis, the Egyptian Experience. Journal of Medical Sciences 2009;9: 98- 102.
15. Hussein ZM, Wagdy R, Shawki M, Zohni S, Shehawy I. The pattern of juvenile idiopathic arthritis; a retrospective Egyptian study. Egypt J Pediatr Allergy Immunol 2018; 16(1):7-14.
16. Bahabri S, Al-Sewairi W, Al-Mazyad A, Karrar A, Al-Ballaa S, El-Ramahai K, et al. Juvenile rheumatoid arthritis: The Saudi experience. Ann Saudi Med 1997; 4:413-8.
17. Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan. Acta PaediatrJpn. 1997;39(2):5–249.
18. Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family – balance between agonists and antagonists in inflammatory diseases. Cytokine 2015;76(1):25–37.
19. Toplak N, Blazina S, Avcin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des DevelTher 2018; 12:1633-43.
20. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012;12:56–9.
21. Castaneda S, Blanco R, Gonzalez-Gay MA. Adult-onset Still’s disease: advances in the treatment. Best Prac Res Clin Rheumatol. 2016;30(2):222-38.
22. Kessel C, Lippitz K, Weinhage T, Hinze C, Wittkowski H, Holzinger D, et al. Proinflammatory cytokine environmentas can drive interleukin-17 overexpression by γ/δ T cells in systemic juvenile idiopathic arthritis. ArthritsRheumatol. 2017;69(7):1480-94.
23. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al, International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2
24. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006;54(5):1595–601.
25. Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep 2014;6:21.
26. Cimaz R. Systemic onset juvenile idiopathic arthritis. Autoimmun Rev 2016;15(9):931–4.
27. Tibaldi J, Pistorio A, Aldera E, Puzone L, El Miedany Y, Pal P, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(11):3505-14.
28. Woerner A, von Scheven-Gête A, Cimaz R, Hofer M. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol. 2015 May;11(5):575-88. doi: 10.1586/1744666X.2015.1032257.
29. Ravelli A, Minoia F, Davi S, Horne AC, Bovis F, Pistorio A, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. A European League Against Rheumatism/American College of Rheumatology/ Pediatric Rheumatology International Trials Organization Collaborative Initiative. Arthritis Rheumatol 2016. DOI 10.1002/ART.39332
30. Çakan M, Karadag SG, Tanatar A, Ayaz NA. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis. Mod Rheumatol2020; 30(5):900-4.
31. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133–8
32. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as a part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13(4):289–98.
33. De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R, Allen R,et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67(3):840–848.
34. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.
35. Ringold S, Weiss PF, Beukelman T, EM DW, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499–512.
36. Correll CK, Binstadt BA. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr Res 2014;75(1–2):176–83.
37. Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034–43.
38. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 2012;64(7):1001–10.
39. Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with Tocilizumab. J Rheumatol. 2015;42(4):712-22.
40. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38(1):180–1.
41. Canny S, Mellins E. New frontiers in the treatment of systemic juvenile idiopathic arthritis. F1000Res 2017;6:971.
42. Canna SW, Girard C, Malle L, de Jesus A, Romberg N, KelsenJ,et al. Life threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol 2017;139(5):1698–701.
43. Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics 2019; 143(5):e20182845.
44. Sandborg C, Holmes TH, Lee T, Biederman K, Bloch DA, Emery H, et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol 2006;33(11):2322–9.
45. Russo RA, Katsicas MM. Patients with very early onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol 2013;40(3):329–34.
46. Boom, V., Anton, J., Lahdenne, P. et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol 13, 55 (2015). https://doi.org/10.1186/s12969-015-0055-3
47. Ambler WG, Nanda K, Onel KB, Shenoi S. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Ann Med. 2022 Dec;54(1):1839-1850.
48. Shenoi S, Wallace CA. Diagnosis and Treatment of Systemic Juvenile Idiopathic Arthritis. J Pediatr. 2016 Oct;177:19-26. doi: 10.1016/j.jpeds.2016.06.056. Epub 2016 Aug 4. PMID: 27499217.
49. WHO. World Health Organization Model List of Essential Medicines. Vol. 22nd List. 2021.
50. Brouwers MC, Kerkvliet K, Spithoff K. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. Bmj. Mar 8 2016;352:i1152. doi:10.1136/bmj.i1152
51. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. Dec 2010;63(12):1308-11. doi:10.1016/j.jclinepi.2010.07.001
52. Song Y, Alonso-Coello P, Ballesteros M, et al. A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Ann Intern Med. May 2022;175(5):710-719. doi:10.7326/m21-4352
53. AGREE Tools. The AGREE Research Trust. 2024. www.agreetrust.org
54. Abdel Baky A, Omar TEI, Amer YS, the Egyptian Pediatric Clinical Practice Guidelines C. Adapting global evidence-based practice guidelines to the Egyptian healthcare context: the Egyptian Pediatric Clinical Practice Guidelines Committee (EPG) initiative. Bulletin of the National Research Centre. 2023/06/13 2023;47(1):88. doi:10.1186/s42269-023-01059-0
55. Alshehri A, Almazrou S, Amer Y. Methodological frameworks for adapting global practice guidelines to national context in the Eastern Mediterranean Region. East Mediterr Health J. Jul 31 2023;29(7):540-553. doi:10.26719/emhj.23.070
56. Amer YS, Elzalabany MM, Omar TI, Ibrahim AG, Dowidar NL. The 'Adapted ADAPTE': an approach to improve utilization of the ADAPTE guideline adaptation resource toolkit in the Alexandria Center for Evidence-Based Clinical Practice Guidelines. Journal of evaluation in clinical practice. Dec 2015;21(6):1095-106. doi:10.1111/jep.12479
57. Klugar M, Lotfi T, Darzi AJ, et al. GRADE guidance 39: using GRADE-ADOLOPMENT to adopt, adapt or create contextualized recommendations from source guidelines and evidence syntheses. J Clin Epidemiol. Aug 6 2024;174:111494. doi:10.1016/j.jclinepi.2024.111494